Lupin appoints Jeffrey Kindler and Alfonso Zulueta to its Board

Pharmaceutical giant Lupin Limited strengthens its leadership team with the addition of Jeffrey Kindler and Alfonso Zulueta as Independent Directors, enhancing strategic vision and industry insights for future growth

0
134
New Delhi: Lupin Limited, a leading pharmaceutical company, has announced the addition of Jeffrey Kindler and Alfonso “Chito” Zulueta to its Board of Directors as Independent Directors.
Jeffrey Kindler brings a depth of experience as a healthcare executive, investor, and advisor, with over four decades of business expertise. He has held esteemed leadership positions at globally renowned companies such as Pfizer, where he served as Chairman & Chief Executive Officer. Prior to that, he contributed significantly to companies like McDonald’s Corporation and General Electric Company. Mr. Kindler is currently the CEO of Centrexion Therapeutics, Senior Advisor to Blackstone, Operating Partner at ARTIS Ventures and Global Chair of GLG Institute. He is also a board member of various companies, including Precigen Inc., Perrigo Pharmaceuticals, and Terns Pharmaceuticals. 
Alfonso “Chito” Zulueta boasts a distinguished career spanning over three decades at Eli Lilly and Company, where he held several key roles, including Vice President of Global Marketing, President of Global Oncology and Critical Care Products and most recently, as President of International responsible for all geographies outside the United States and Canada. He served as a corporate officer and member of Eli Lilly and Company’s Executive Committee. Currently, he serves as the Non-Executive Chairman of the board of directors of Interpharma Investments Limited, a member of the board of directors at Glooko, CTS Corporation, and Bridge PayDay Solutions and is the president/CEO of CZ Ventures. 
Vinita Gupta, Chief Executive Officer of Lupin, expressed her delight at the appointments, stating, “We are delighted to welcome Jeff and Chito to our board. Their extensive experience in building healthcare institutions, strategic perspectives of our industry, and deep understanding of the evolving global pharmaceutical landscape will enable us to advance our growth plans in the years to come.”